Lanadelumab efficacy after switching from placebo: results from the help and help open-label extension studies

Lanadelumab significantly reduced hereditary angioedema (HAE) attack rates versus placebo over 26 weeks in the phase 3 double-blind (DB) HELP Study (NCT02586805). Patients who completed the DB continued into the ongoing open-label extension study (OLE; NCT02741596). This interim analysis of data from 26May2016-01Sept2017 evaluated lanadelumab efficacy in the OLE among patients who received placebo in the DB.

Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: R. Tachdjian, J. Anderson, P. Busse, D. Johnston, S. Kiani, C. Nurse, K. Paes Tags: P171 Source Type: research